Rifapentine, Moxifloxacin, or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model

Rationale: Priorities for developing improved regimens for treatment of latent tuberculosis (TB) infection include (1) developing shorter and/or more intermittently administered regimens that are easier to supervise and (2) developing and evaluating regimens that are active against multidrug-resista...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Nuermberger, Eric, Tyagi, Sandeep, Williams, Kathy N., Rosenthal, Ian, Bishai, William R., Grosset, Jacques H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Thoracic Society 2005
Gaiak:
I. Tuberculosis
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC1853317/
https://ncbi.nlm.nih.gov/pubmed/16151038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1164/rccm.200507-1047OC
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak